Challenges in assessing inhaled biologics in pre-clinical models - Virtual school of nebulisation of drugs for treatment of respiratory infections and disease - February 2025

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Virtual school of nebulisation of drugs for treatment of respiratory infections and disease - February 2025

This course was organised in collaboration with the FAIR project. Learn more about the FAIR project.

When considering the respiratory environment and particularly the lower respiratory tract, nebulisation has emerged as one of the most useful routes of administration to treat pulmonary disease, owed to its direct lung delivery and its ease in use by both the young and the elderly.

This course provided useful information on the current state-of-the-art use for nebulisation in the pulmonary field.

Session 2 - Pre-clinical models to assess nebulisation effectiveness

Chair(s): Nathalie Heuze Vourc'h, Jean-Claude Sirard

Session type: Lecture

Challenges in assessing inhaled biologics in pre-clinical models

Rita Vanbever

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

Challenges in assessing inhaled biologics in pre-clinical models

Rita Vanbever

Replay

Slides

In vivo influenza pig model for inhaled vaccines development

Elma Tchilian

Replay

Slides

In vitro human lung models to evaluate safety and efficacy of inhaled therapeutics

Samuel Constant

Replay

Slides

Discussion Q&A, quiz

Replay

Lunch

Virtual school of nebulisation of drugs for treatment of respiratory infections and disease - February 2025

#{title}